CAS 913612-38-1

Brexpiprazole dihydrochloride

Description:

Brexpiprazole dihydrochloride is an atypical antipsychotic medication primarily used in the treatment of schizophrenia and as an adjunctive therapy for major depressive disorder. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, while also functioning as an antagonist at serotonin 5-HT2A receptors, which contributes to its therapeutic effects. The substance is characterized by its relatively high oral bioavailability and a long half-life, allowing for once-daily dosing. It is typically administered in the form of tablets and is well-absorbed in the gastrointestinal tract. Common side effects may include weight gain, akathisia, and sedation, although it is generally considered to have a favorable side effect profile compared to other antipsychotics. The dihydrochloride salt form enhances its solubility and stability, making it suitable for pharmaceutical formulations. As with any medication, it is essential to use brexpiprazole under the guidance of a healthcare professional, considering potential interactions and contraindications.

Formula: C₂₅H₂₈ClN₃O₂S

Synonyms:

• Brexpiprazole HCl
• Brexpiprazole dihydrochloride
• antipsychotic,OPC34712,OPC-34712,Serotonin Receptor,5-hydroxytryptamine Receptor,Brexpiprazole,recognition deficits,Dopamine Receptor,Beta Receptor,neurite outgrowth,Adrenergic Receptor,Brexpiprazole HCl,PC12,5-HT Receptor,Inhibitor,OPC 34712,orally active,inhibit
• OPC 34712 dihydrochloride

Brexpiprazole HCl

CAS: 913612-38-1

Brexpiprazole HCl

Purity: ≥98%

Molecular weight: 433.6g/mol

Ref: 54-BUP12205

Brexpiprazole HCl

CAS: 913612-38-1

Brexpiprazole HCl (OPC 34712 dihydrochloride) is a new antipsychotic drug.

Formula: C₂₅H₂₇N₃O₂S·xHCl

Purity: 99.05%

Color and Shape: Solid

Molecular weight: 433.6

Ref: TM-T8690

Brexpiprazole dihydrochloride

CAS: 913612-38-1

Brexpiprazole dihydrochloride is a drug that belongs to the group of antipsychotics. It is a partial agonist at serotonin receptors, with high affinity for 5HT2A and 5HT1A receptors. Brexpiprazole dihydrochloride has been shown to be effective in treating schizophrenia, bipolar disorder, and major depressive disorder. Brexpiprazole dihydrochloride is a prodrug that is converted by esterases into brexpiprazole, its active form. The conversion of brexpiprazole dihydrochloride to brexpiprazole occurs in the blood and the brain.

Formula: C₂₃H₁₃F₉N₄O₃S

Purity: Min. 95%

Molecular weight: 596.4 g/mol

Ref: 3D-NLB61238